for the Period Ended 31 May 2024
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 May 2024
Directors
The directors shown below have held office during the whole of the period from
1 June 2023
to
31 May 2024
The director shown below has held office during the period of
6 October 2023
to
31 May 2024
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
2024 | 2023 | |
---|---|---|
|
£ |
£ |
Turnover: |
|
|
Cost of sales: |
(
|
(
|
Gross profit(or loss): |
|
( |
Administrative expenses: |
(
|
(
|
Other operating income: |
|
|
Operating profit(or loss): |
( |
|
Profit(or loss) before tax: |
( |
|
Tax: |
(
|
|
Profit(or loss) for the financial year: |
( |
|
As at
Notes | 2024 | 2023 | |
---|---|---|---|
|
£ |
£ |
|
Fixed assets | |||
Tangible assets: | 3 |
|
|
Total fixed assets: |
|
|
|
Current assets | |||
Cash at bank and in hand: |
|
|
|
Total current assets: |
|
|
|
Creditors: amounts falling due within one year: | 4 |
(
|
(
|
Net current assets (liabilities): |
( |
( |
|
Total assets less current liabilities: |
( |
|
|
Total net assets (liabilities): |
( |
|
|
Members' funds | |||
Profit and loss account: |
( |
|
|
Total members' funds: |
( |
|
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 May 2024
Basis of measurement and preparation
Turnover policy
Tangible fixed assets depreciation policy
for the Period Ended 31 May 2024
2024 | 2023 | |
---|---|---|
Average number of employees during the period |
|
|
for the Period Ended 31 May 2024
Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
---|---|---|---|---|---|---|
Cost | £ | £ | £ | £ | £ | £ |
At 1 June 2023 |
|
|
||||
Additions |
|
|
||||
Disposals |
|
|
||||
Revaluations | ||||||
Transfers | ||||||
At 31 May 2024 |
|
|
||||
Depreciation | ||||||
At 1 June 2023 |
|
|
||||
Charge for year |
|
|
||||
On disposals |
|
|
||||
Other adjustments |
|
|
||||
At 31 May 2024 |
|
|
||||
Net book value | ||||||
At 31 May 2024 |
|
|
||||
At 31 May 2023 |
|
|
for the Period Ended 31 May 2024
2024 | 2023 | |
---|---|---|
£ | £ | |
Accruals and deferred income |
|
|
Total |
|
|
Our organisation creates and delivers Sickle Cell educational programmes and events in UK and worldwide. This year we continued our work with a pharmaceutical company to raise awareness of Sickle Cell and delivered our ‘Conversations with Jen’ programme – and toured across different regions. The programme promoted dialogue amongst sickle cell sufferers and wider communities. The programme successfully highlighted the importance of being able to support people in the community who live with the condition. Our work with NHS Blood and Transplant through our community programme started and has allowed us to widen our reach and create opportunities for diversity and inclusion. This includes blood donation campaigns and events to recruit more black and Asian donors. The Progression of Sickle Cell conference and gala was held in Birmingham. The first of its kind, this was an education and awareness conference - giving the community more time to learn about Sickle Cell. The fund raising gala honored and celebrated those that have contributed to the progression of sickle cell.
Our work with blood and transplant teams in the NHS have provided a voice for young people living with sickle cell feel accepted and understood by the wider community. The events have been well attended, by sickle cell sufferers and those who did not have any awareness of sickle cell. nearly 5,000 followers on social media platforms 150 attended the Progression of Sickle Cell conference and gala Practical Workshop, the Sickle Cell series across regional locations In education and driving awareness our organisation aims is to grow advocates in the UK and worldwide to increase blood donations and to build strategies for those living with the condition
Directors remuneration is £5,200 in the year.
No transfer of assets other than for full consideration
This report was approved by the board of directors on
24 February 2025
And signed on behalf of the board by:
Name: Jenica Leah GREGORY
Status: Director